Outcomes of SARS-CoV-2 infected pregnancies after medically assisted reproduction

dc.contributor.authorBaris, Ata
dc.contributor.authorLuca, Gianaroli
dc.contributor.authorKersti, Lundin
dc.contributor.authorSaria, Mcheik
dc.contributor.authorEdgar, Mocanu
dc.contributor.authorRautakallio-Hokkanen, Satu
dc.contributor.authorTapanainen, Juha S.
dc.contributor.authorVermeulen, Nathalie
dc.contributor.authorVeiga, Anna
dc.date.accessioned2022-02-11T16:35:28Z
dc.date.available2022-02-11T16:35:28Z
dc.date.issued2021
dc.description.abstractThe role of certain viruses in the etiology of some tumors is today indisputable, but there is a lack, however, of an overview of the relationship between viruses and cancer with a multidisciplinary approach. For this reason, the Health Sciences Foundation has convened a group of professionals from different areas of knowledge to discuss the relationship between viruses and cancer, and the present document is the result of these deliberations. Although viruses cause only 10-15% of cancers, advances in oncology research are largely due to the work done during the last century on tumor viruses. The clearest cancer-inducing viruses are: HPV, HBV, HCV, EBV and, depending on the geographical area, HHV-8, HTLV-1 and HIV. HPVs, for example, are considered to be the causative agents of cervical carcinomas and, more recently, of a proportion of other cancers. Among the Herpes viruses, the association with the development of neoplasms is well established for EBV and HHV-8. Viruses can also be therapeutic agents in certain neoplasms and, thus, some oncolytic viruses with selective tropism for tumor cells have been approved for clinical use in humans. It is estimated that the prophylaxis or treatment of viral infections could prevent at least 1.5 million cancer deaths per year.ca
dc.format.extent8 p.
dc.format.mimetypeapplication/pdf
dc.identifier.citationAta, B., Gianaroli, L., Lundin, K., Mcheik, S., Mocanu, E., Rautakallio-Hokkanen, S., ... & Veiga, A. (2021). Outcomes of SARS-CoV-2 infected pregnancies after medically assisted reproduction. Human Reproduction, 36(11), 2883-2890.ca
dc.identifier.issn1460-2350
dc.identifier.pmid34515777
dc.identifier.urihttps://hdl.handle.net/2445/183116
dc.language.isoengca
dc.publisherOxford Academic Pressca
dc.relation.isformatofReproducció del document publicat a: https;//doi.org/10.1093/humrep/deab218
dc.relation.ispartofHuman reproduction, 2021, vol 36, num 11, p. 2883-2890
dc.relation.urihttps;//doi.org/10.1093/humrep/deab218
dc.rightscc by-nc (c) Baris, Ata et al, 2021
dc.rights.accessRightsinfo:eu-repo/semantics/openAccessca
dc.rights.urihttp://creativecommons.org/licenses/by-nc/3.0/es/*
dc.sourceArticles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))
dc.subject.classificationCOVID-19
dc.subject.classificationReproducció assistida
dc.subject.otherCOVID-19
dc.subject.otherReproductive technology
dc.titleOutcomes of SARS-CoV-2 infected pregnancies after medically assisted reproductionca
dc.typeinfo:eu-repo/semantics/articleca
dc.typeinfo:eu-repo/semantics/publishedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
deab218.pdf
Mida:
313.46 KB
Format:
Adobe Portable Document Format
Descripció: